Skip to main content
. 2022 Jun 13;13(6):548. doi: 10.1038/s41419-022-04997-1

Fig. 7. Promotion of the Hsp90-Acsl4 pathway enhances erastin sensitivity in vivo.

Fig. 7

A Mice were subcutaneously and intracranially xenografted with PG7 cells of different groups (5 × 106/5 × 105 cells) and treated intraperitoneally with erastin (10 mg kg−1 day−1 per mouse) or DMSO (0.3%) twice, every two days. B Diameter of subcutaneous tumors. Data indicated as mean ± S.D. (n = 6 mice per group). C Image of subcutaneous tumors. D Tumor weight of subcutaneous tumors. Data are indicated as mean ± S.D. (n = 6 mice per group). E Kaplan–Meier survival of mice. (n = 6 mice per group). F Weight of mice during the experiment. Data indicated as mean ± S.D. (n = 6 mice per group). G Bioluminescence imaging was performed on days 7, 14, 21, and 28 after implantation. *p < 0.05, **p < 0.01, ***p < 0.001.